[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557089":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":32,"centralContacts":36,"locations":46,"responsibleParty":189,"collaborators":11,"id":191,"slug":11,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":11,"eligibilityCriteria":196,"healthyVolunteers":192,"sex":197,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":11,"studyType":203,"phases":204,"briefSummary":207,"conditions":208,"keywords":222,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":235},{"fullName":5,"class":6},"Vironexis Biotherapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1\u002FGroup 2\u002FGroup 3\u002FGroup 4","EXPERIMENTAL",null,[13,14,15,16],"Genetic: Dose Level 1, VNX-101","Genetic: Dose Level 2, VNX-101","Genetic: Dose Level 3, VNX-101","Genetic: Dose Level 4, VNX-101",[18,23,26,29],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"GENETIC","Dose Level 1, VNX-101","Adeno-associated viral vector encoding the CD3\u002FCD19 Bi-Specific T-Cell Engager (AAV.CD3\u002FCD19), Single IV infusion",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":11},"Dose Level 2, VNX-101",[9],{"type":19,"name":27,"description":21,"armGroupLabels":28,"otherNames":11},"Dose Level 3, VNX-101",[9],{"type":19,"name":30,"description":21,"armGroupLabels":31,"otherNames":11},"Dose Level 4, VNX-101",[9],[33],{"name":34,"affiliation":5,"role":35},"Vironexis Clinical Trials","STUDY_DIRECTOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Allen Reha","CONTACT","908-938-6019","allen.reha@vironexis.com",{"name":43,"role":39,"phone":44,"phoneExt":11,"email":45},"Recruitment Partner: PatientWing","213-459-2979","studies@patientwing.com",[47,67,81,95,114,129,144,159,174],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":55,"coordinates":56},"Point",[57,58],-117.97729,34.13945,{"lat":58,"lon":57},[61,65],{"name":62,"role":39,"phone":63,"phoneExt":11,"email":64},"Anthony Stein, MD","877-467-3411","AStein@coh.org",{"name":62,"role":66,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":68,"status":49,"city":69,"state":51,"zip":70,"country":53,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Valkyrie Clinical Trials","Los Angeles","90067",{"type":55,"coordinates":72},[73,74],-118.24368,34.05223,{"lat":74,"lon":73},[77],{"name":78,"role":39,"phone":79,"phoneExt":11,"email":80},"Myo Zaw","424-535-1874","clinicaltrials@vctcare.com",{"facility":82,"status":49,"city":83,"state":84,"zip":85,"country":53,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Colorado Blood Cancer Institute","Denver","Colorado","80218",{"type":55,"coordinates":87},[88,89],-104.9847,39.73915,{"lat":89,"lon":88},[92],{"name":93,"role":39,"phone":94,"phoneExt":11,"email":11},"Clinical Trial Information Line","720-754-4835",{"facility":96,"status":49,"city":97,"state":98,"zip":99,"country":53,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"New York Medical College","Valhalla","New York","10595",{"type":55,"coordinates":101},[102,103],-73.77513,41.07482,{"lat":103,"lon":102},[106,110,113],{"name":107,"role":39,"phone":108,"phoneExt":11,"email":109},"Mitchell Cairo, MD","914-594-2150","mitchell_cairo@nymc.edu",{"name":111,"role":39,"phone":11,"phoneExt":11,"email":112},"Lauren Harrison","lauren_harrison@nymc.edu",{"name":107,"role":66,"phone":11,"phoneExt":11,"email":11},{"facility":115,"status":49,"city":116,"state":117,"zip":118,"country":53,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"University of North Carolina at Chapel Hill\u002F University of North Carolina Medical Center","Chapel Hill","North Carolina","27599",{"type":55,"coordinates":120},[121,122],-79.05584,35.9132,{"lat":122,"lon":121},[125],{"name":126,"role":39,"phone":127,"phoneExt":11,"email":128},"Lacey Williams, MD","919-445-9676","Lacey_Williams@med.unc.edu",{"facility":130,"status":49,"city":131,"state":132,"zip":133,"country":53,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"The Ohio State University Wexner Medical Center","Columbus","Ohio","43210",{"type":55,"coordinates":135},[136,137],-82.99879,39.96118,{"lat":137,"lon":136},[140],{"name":141,"role":39,"phone":142,"phoneExt":11,"email":143},"Gregory Behbehani, MD, PhD","614-293-3316","gregory.behbehani@osumc.edu",{"facility":145,"status":49,"city":146,"state":147,"zip":148,"country":53,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Oregon Health & Science University","Portland","Oregon","97239",{"type":55,"coordinates":150},[151,152],-122.67621,45.52345,{"lat":152,"lon":151},[155],{"name":156,"role":39,"phone":157,"phoneExt":11,"email":158},"Knight Cancer Institute Clinical Trials","503-949-1080","trials@ohsu.edu",{"facility":160,"status":49,"city":161,"state":162,"zip":163,"country":53,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"TriStar BMT","Nashville","Tennessee","37203",{"type":55,"coordinates":165},[166,167],-86.78444,36.16589,{"lat":167,"lon":166},[170],{"name":171,"role":39,"phone":172,"phoneExt":11,"email":173},"Stephen Strickland, MD","615-329-7274","stephen.strickland@hcahealthcare.com",{"facility":175,"status":49,"city":176,"state":177,"zip":178,"country":53,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":55,"coordinates":180},[181,182],-95.36327,29.76328,{"lat":182,"lon":181},[185],{"name":186,"role":39,"phone":187,"phoneExt":11,"email":188},"Nicholas J Short, MD","713-563-4485","NShort@Mdanderson.org",{"type":190,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100557089",false,"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","A Phase 1\u002F2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)","Inclusion Criteria:\n\n* Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age\n* Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol\n* CD19-positive expression\n* AAV specified capsid total antibody \\\u003C1:400\n* Protocol-specified ranges for renal, liver, cardiac and pulmonary function\n* Protocol-specified ranges for hematology parameters\n\nExclusion Criteria:\n\n* Hepatoxicity (AST or ALT \\> 2x upper limit of normal)\n* History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy\n* Pregnant or nursing (lactating) women\n* Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade\n* History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity\n* Chemotherapy given within the protocol-specified discontinuation timelines\n\nOther Inclusion\u002FExclusion criteria to be applied per protocol.","ALL","13 Years","90 Years",{"count":201,"type":202},32,"ESTIMATED","INTERVENTIONAL",[205,206],"PHASE1","PHASE2","This is a Phase 1\u002F2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.",[209,210,211,212,213,214,215,216,217,218,219,220,221],"B-cell Acute Lymphoblastic Leukemia","Large B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Burkitt Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Non Hodgkin Lymphoma","Mixed Phenotype Acute Leukemia",[223,224,225],"CD19-positive","Leukemia","Lymphoma","2026-03-24",{"date":228,"type":229},"2026-03-30","ACTUAL",{"date":231,"type":229},"2025-05-30",{"date":233,"type":202},"2031-09",{"name":5,"class":6},9]